The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Auxilium Pharmaceuticals's revenues will increase 15.8% and EPS will wane -50.0%.
The average estimate for revenue is $90.6 million. On the bottom line, the average EPS estimate is $0.08.
Last quarter, Auxilium Pharmaceuticals reported revenue of $66.2 million. GAAP reported sales were 10% lower than the prior-year quarter's $73.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.12. GAAP EPS were -$0.17 for Q1 versus -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.2%, 20 basis points worse than the prior-year quarter. Operating margin was -7.7%, 510 basis points worse than the prior-year quarter. Net margin was -12.3%, 990 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $371.8 million. The average EPS estimate is $0.37.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 148 members out of 201 rating the stock outperform, and 53 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Auxilium Pharmaceuticals a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.80.
- Add Auxilium Pharmaceuticals to My Watchlist.